In short
Clinical trials are studying GSKVX000000070250 in adults 18 years and older with influenza-related vaccination research. These studies look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination.
Key points
- Clinical trials of GSKVX000000070250 are studying influenza vaccination in adults 18 years and older. Both trials are Phase 2 interventional studies. The main goals are to measure immune response and safety. Researchers are looking at antibody levels, seroconversion, seroprotection, and short-term as well as longer-term safety outcomes. The available trials include one completed study and one authorised study.
Trial overview
Two Phase 2 clinical trials are studying GSKVX000000070250 in the setting of influenza vaccination research. Both studies are interventional, which means researchers give study vaccines and then measure the results.
Both trials focus on influenza, Human, and both aim to evaluate immune response and safety. The source data describes GSKVX000000070250 as one of several study interventions used in these flu vaccine trials.
Who is being studied
The trials are in adults 18 years of age and older. The source data does not give more detailed inclusion or exclusion rules, so the available information only confirms the adult age group.
These studies are meant for people who can take part in influenza vaccine research, not for children or adolescents, based on the trial titles and descriptions provided.
What the trials measure
The main immune outcome is the antibody titer for antigen 1 at Day 29, along with the fold increase from Day 1 to Day 29. Antibody titer is a blood test measure that shows how much antibody the body has made after vaccination.
The trials also measure seroconversion and seroprotection at Day 1 and Day 29. Seroconversion means a person develops a measurable antibody response, while seroprotection means the antibody level is thought to provide protection.
Safety is also a major goal, with tracking of solicited administration site or systemic events within 7 days, unsolicited adverse events within 28 days, serious adverse events within 6 months, adverse events of special interest within 6 months, medically attended adverse events within 6 months, and laboratory abnormalities at several time points after dosing.
In simple terms, the studies are checking both how well the vaccine response works and how the body tolerates the study vaccines over time.
Trial status and size
One trial, 2025-522278-35-00, is listed as Completed and includes 770 participants. The other trial, NCT07204964, is listed as Authorised and includes 960 participants.
Together, these studies show that GSKVX000000070250 is being tested in a moderate-size Phase 2 program focused on flu vaccination outcomes.
Study design and vaccine comparisons
The trial data shows that GSKVX000000070250 is compared with other influenza vaccine options, including an inactivated split virus vaccine and a recombinant influenza vaccine. These names refer to different ways flu vaccines are made, but the source data does not go into more detail about how they work.
Both trials use a 0.5 ml intramuscular dose, meaning the study vaccine is given into a muscle in a 0.5 millilitre amount. The source data does not provide the full schedule of all doses, so only the listed administration details are included here.
What these results mean for patients
For patients, these trials are mainly about whether the flu vaccine study groups can create a strong antibody response and whether the vaccines are well tolerated. The most important results are the immune markers at Day 29 and the safety findings collected soon after vaccination and over the following months.
Because the available data comes from Phase 2 influenza vaccine studies, the focus is on learning more about performance and safety in adults before any later-stage research decisions.